<DOC>
	<DOCNO>NCT01719627</DOCNO>
	<brief_summary>Pre-exposure prophylaxis ( PrEP ) method prevent HIV infection use antiretroviral ( ARV ) medication exposure HIV . This study assess potential MVC `` demand '' pre-exposure prophylaxis , within strategy prevention HIV infection men sex men ( MSM ) .</brief_summary>
	<brief_title>First Study Evaluate Capacity Maraviroc Drug Protect Against HIV Infection Samples Rectal Mucosa From Healthy Volunteers</brief_title>
	<detailed_description>Several clinical trial currently way evaluate safety effectiveness ARV-based PrEP prevent HIV infection . The result first efficacy trial ARV-based PrEP show few HIV infection among study participant receive study drug compare receive placebo . Although result promise , concern adherence , pharmacokinetics , toxicity still need exploration new effective preventive pharmacological approach evaluate . This trial evaluate safety , pharmacokinetics efficacy ex vivo HIV infection rectal mucosa CCR5 antagonist drug maraviroc ( Selzentry ) administer healthy volunteer . This trial last approximately one year . Twenty-one volunteer receive MVC 300 mg orally single dose . Study visit occur enrollment day 0 , 7 , 9 , 14 16 . All study visit include physical examination , blood collection storage basal visit day 7 9 participant undergo colonoscopy . Ex vivo HIV infectivity rectal mucosa biopsy plasma/mucosa MVC level evaluate .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Maraviroc</mesh_term>
	<criteria>1 . Men sex men ( MSM ) 2 . Age 18 year 3 . HIV negative time inclusion 4 . Signed informed consent 1 . Existence sexually transmit infection ( STI ) active systemic infection 2 . Submit contraindication rectal biopsy 3 . Take drug concomitantly interaction MVC 4 . Subject unable follow protocol</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>HIV , Maraviroc , PrEP , Ex vivo infection , rectal mucosa .</keyword>
</DOC>